With more than 250 votes cast, Jennifer Doudna is leading by a decisive margin in a poll asking who deserves the patent for use of CRISPR-Cas9 as a tool. Feng Zhang got only just over half the votes of Doudna. Another take home message from this poll is that a sizable minority–almost one in five– said neither should have a patent on this technology. Geographically the results were fairly consistent across countries, but notably in the UK the top response was, “Neither”. This poll is …Read More
A lot has happened in the week since the first human embryo genetic modification paper was published by a team led by Junjiu Huang. There have been a number of new events just in the last few days. Jocelyn Kaiser over at SCIENCEINSIDER has a new piece reporting a couple important developments including that the journal that published the human embryo editing paper, Protein & Cell, has issued an editorial explaining the review process for the paper. They argue that the review was fast, but …Read More
There is no hotter technology than CRISPR-Cas9 gene editing tools. Perhaps it is not surprising then that there is a patent dispute over it, which falls into two camps: (1) Jennifer Doudna & Emmanuelle Charpentier, and (2) Feng Zhang. Who deserves the intellectual property for use of CRISPR-Cas9 in human cells? Take our poll.
I’m doing a series of interviews with leaders in the field on human germline modification with the first interview in this series with George Church and today’s second in this series is a conversation I had with Dr. Jennifer Doudna, a pioneer in CRISPR-Cas9 technology. Doudna is a Professor in MCB and Chemistry as well as Li Ka Shing Chancellor’s Chair in Biomedical and Health Sciences at UC Berkeley. She is also an HHMI Investigator. You can read more about the Doudna lab’s research here. …Read More